Keudell Morrison Wealth Management Reduces Stock Position in Sanofi (NASDAQ:SNY)

Keudell Morrison Wealth Management lowered its position in shares of Sanofi (NASDAQ:SNY) by 4.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,711 shares of the company’s stock after selling 551 shares during the period. Keudell Morrison Wealth Management’s holdings in Sanofi were worth $733,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Manning & Napier Advisors LLC bought a new position in shares of Sanofi in the 2nd quarter worth about $13,725,000. Mount Yale Investment Advisors LLC increased its stake in shares of Sanofi by 44.3% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after acquiring an additional 12,806 shares in the last quarter. Sei Investments Co. increased its stake in shares of Sanofi by 9.3% in the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock worth $26,926,000 after acquiring an additional 47,297 shares in the last quarter. Atria Investments Inc increased its stake in shares of Sanofi by 31.1% in the 1st quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock worth $4,805,000 after acquiring an additional 23,463 shares in the last quarter. Finally, GFS Advisors LLC increased its stake in shares of Sanofi by 1,017.9% in the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after acquiring an additional 11,655 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on SNY shares. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Argus raised their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Price Performance

NASDAQ:SNY traded up $0.29 during trading hours on Thursday, hitting $51.55. 97,366 shares of the stock traded hands, compared to its average volume of 2,022,523. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 1 year low of $45.13 and a 1 year high of $58.97. The company has a market cap of $130.83 billion, a price-to-earnings ratio of 26.15, a price-to-earnings-growth ratio of 1.35 and a beta of 0.61. The stock has a 50 day moving average price of $55.78 and a 200 day moving average price of $52.15.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the previous year, the firm earned $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. Sell-side analysts forecast that Sanofi will post 4.27 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.